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Abstract There is a currently a general trend towards organ-preserving surgery, and urology is no 
exception. Specifically, nephron-sparing surgery (NSS) has gained general acceptance for T1a 
renal cell carcinoma (guidelines recommendations). Moreover T1b, T2 and even T3 stage tumors 
have been included on the nephron sparing list at some centers. An unresolved issue is that of 
positive surgical margins (PSM), not only their detection but also the implications for follow up 
and treatment. This paper highlights data available on risk factors for PSM, their clinical 
relevance, and possible therapeutic consequences.   
From the surgeon’s viewpoint, NSS is a daring and risky surgical procedure. Urological 
guidelines stress the importance of NSS, and thus the trend is moving in that direction. 
Unresolved, however, is the problem of PSM. Trifecta, MIC, and pentafecta are applicable 
concepts which attempt to define the optimal endpoint of NSS, but further elaboration is 
necessary. Specifically, research needs to focus less on the concept of definitive margins and 
more on their identification and avoidance. Although some studies suggest that PSMs do not 
influence overall survival rate, the basic idea of preserving tissue that is not cancerous leads to 
further medical, social, and psychological considerations.   
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Highlights ✓ Nephron-sparing surgery is considered today by several studies a daring and a risky 
surgical procedure, with important (medical, psychological and social) implications 
✓ Positive surgical margin needs to be investigated more not as a definition, but for means 
of identification/ avoidance that is important for an adequate therapeutic approach.  
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Introduction 
Over the past 20 years, nephron-sparing surgery 
(NSS) has evolved rapidly and is now considered the 
standard of care for the treatment of most small renal 
masses. In accordance with international guidelines, 
NSS is being widely used to treat tumours less than 4 
cm. EAU guidelines recommend partial nephrectomy as 
the standard procedure for T1a and T1b renal masses in 
technically feasible cases (1).   
NSS seems to have similar oncological outcomes as 
radical nephrectomy. It is also well suited for minimally 
invasive surgery either in laparoscopy or using a 
robotical approach. Initial indications for NSS relied on 
highly selective cases with single surgical kidney or 
some tumors with feasible layout for surgery. Due to the 
technical evolution and the experience of medical staff 
now available in most centers, NSS is indicated for the 
T1a stage and may be used within certain limits for other 
stages of the disease. 
This change in therapeutic approach is based 
primarily on findings indicating that organ-sparing 
surgery offers the potential for better preservation of 
renal function and a lower risk of cardiovascular 
sequelae. Oncological outcomes appear to be equivalent 
and perioperative morbidity seems to be only minimally 
higher for nephron-sparing interventions. 
Unfortunately, there are few studies to assess the 
significance and impact of the positive surgical margin 
(PSM) on the patient's prognosis and what therapeutic 
possibilities exist. 
 
Discussion 
Research findings related to nephron-sparing 
surgery are variable, beginning with case presentations 
to studies using small series of patients. For instance, 
Lopez-Costea et al. present a group of 137 patients with 
NSS, of which 11 had positive surgical margins (2). 
Along the same line, Kwon et al., in a study of 770 
patients who had open partial nephrectomy, reported a 
total of 57 (7%) with PSMs; two of these had a local 
recurrence compared with four of 713 who had a 
negative margin (0.5%). Patients with a low potential for 
malignancy and PSM did not have a local recurrence (3).    
Of the factors that might explain cases of local 
recurrence having no association with PSMs, the 
presence of tumour multifocality is relevant. Although 
more frequent for other tumour types, it is associated 
with renal cell carcinoma (RCC) and would therefore be 
considered as an independent variable related to tumour 
recurrence. 
Various procedures that could lessen the risk of a 
PSM in the final specimen need to be promoted. These 
include the use of intraoperative ultrasound (US), 
thereby allowing an adequate safety margin, and hilar 
clamping that could provide better distinction between 
healthy and tumorous tissue as well as aid in the correct 
identification of the calyceal system, with the downside 
of longer ischaemia time. Regarding this latter point, 
Yossepowitch et al. noted that, in their series of NSS, 
more PSMs were found in smaller renal masses (4). This 
result was probably due to a poor delimitation of healthy 
and tumourous tissue, the tendency not to use hilar 
clamping, and limiting surgery solely to the tumour. 
Concerning renal ischaemia, Yossepovitch et al. 
suggested that it might cause involution of cells with 
high metabolic activity. Furthermore, others such as 
Gallucci et al. proposed selective embolization of large 
or hilar tumours (5).  
The use of powerful haemostatic systems such as an 
argon-beam or ultrasound scalpel, destroying potential 
tumour cells in the surgical bed, and the application of 
haemostatic materials which could induce direct 
ablation of cells through an inflammatory and/or 
immunological reaction with cytotoxic capacity all 
represent strategies that are available for surgical tumour 
extraction.  
Alharbi et al. studied the use of intraoperative 
ultrasound control of surgical margins during partial 
nephrectomy (PN). Their study was conducted from 
January, 2010 to December, 2015 on patients with T1- 
T2 renal tumors that had undergone PN performed 
through open, laparoscopic or robot-assisted 
laparoscopic approaches. Before tumor removal, 
ultrasound was performed intraoperatively. The tumor 
was removed with the standardized minimal healthy 
tissue margin technique. After resection, ultrasound 
control of the margins was performed. The removed 
tumor was immersed in a saline solution and US was 
performed to evaluate in three dimensions whether the 
tumor capsule was intact. If the margins were negative, 
hemostasis was performed. If not, an extra rim of renal 
parenchyma was removed circumferentially to include 
the entire remaining margin. In their study, 177 PN were 
included, and the results were compared with the 
pathology exam. All except one negative US surgical 
margins were confirmed. In cases where US 
determination was not feasible, the surgical margins 
were negative. Overall, all final surgical margins were 
negative in the pathology exam even when extra rim 
resection of renal parenchyma was required. In 
conclusion, intraoperative US had determined the 
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margin status with 99% sensitivity and 75% specificity. 
Positive and negative predictive values were also 99% 
and 75% (6). 
A study by Nguyen et al. demonstrated a technique 
in which the deep tumor margins were marked by a 
needle implanted in situ under US guidance.  
Costabel et al. recently reported their 10-year 
experience with single kidney patients who had 
undergone nephron sparing surgery. Of the 45 patients, 
4 were found with positive resection margins, and 4 with 
local recurrence (2 of those with positive margins). Of 
those 3, they were in T1a and one in T1b. Most 
important was that the extemporaneous exam was 
negative in all four cases, a thing that does not only 
appear in their work (7). 
One of the most valuable materials and one of the 
few papers dealing with this theme is written by 
Steinestel et al. Their review covers a period of 15 years. 
The authors identified one of the risk factors for PSM as 
the unique kidney condition (either functional or 
anatomical). PSM rates of 9 to 28% are described here 
(8). 
Tumor size is a risk factor about which there is no 
definitive agreement yet. Some authors claim that small 
tumor masses present higher risk, whereas others state 
larger ones present higher risk. Some authors contend 
that size is not a risk factor in itself.  A second factor 
considered by the authors is the tumor topography. 
Although no consensus exists, it is generally accepted 
that medioreal tumor formations present a higher risk of 
PSM. 
Reliance on frozen sections, which theoretically 
should be useful to the urologist, unfortunately presents 
marginal results and generally does not influence the 
prognosis of the disease and the rate of detection of the 
positive margins (9). Microscopic examination 
performed by an intraoperative surgeon appears to have 
better results. More recently, there is a cytology 
proposition that delivers results consistent with the final 
histopathological exam. 
The impact of PSM on local relapse and patient 
survival is controversial. Studies claim that PSM is a 
predictor of relapse and poor prognosis for the disease. 
On the other hand, some authors claim that PSM has no 
value in tracking the patient. The general assumption is 
that microscopic PSMs do not present a risk factor for 
patient survival but that, nevertheless, such situations 
should be avoided. Most positions recommend a 
conservative rather than aggressive approach toward 
surgery. 
Wang et al. evaluated the laparoscopic 
retroperitoneal approach on 53 patients. The resection 
limit was 5 mm and one patient presented PSM but no 
relapse at 56 months. Their PSM recommendation 
includes surveillance and imaging surveillance (10). 
On 63 patients who underwent laparoscopic partial 
nephrectomy Osaka et al. found 4 patients (6,3%) with 
positive surgical margins. The aim of their study was to 
evaluate the predictors of trifecta outcomes for 
laparoscopic partial nephrectomy for T1a renal masses 
(11). 
Joniau et al. studied the outcome of nephron-
sparing surgery for T1b renal cell carcinoma on a group 
of 67 patients (average age – 62) with T1b carcinoma 
tumors 4-7 cm. They monitored tumor characteristics, 
surgical indication, complications of recurrence, and 
time-to-death. Positive margins were diagnosed in 4 
patients (6%). None of these patients developed distant 
or local metastases within 3 years. Of these patients, 2 
ranked Fuhrman III and the other 2 Fuhrman II grades. 
None had any surgical indication for reintervention. The 
renal ischemia time was 14 minutes on average, using 
both the renal pedicle clamping method and 
hypothermia (12). 
Smith et al. developed a technique for tumor 
enucleation for renal cell carcinoma involving the use of 
tumor pseudocapsules to remove as little healthy kidney 
tissue as possible. Traditionally, the 1 cm margin of the 
enucleated tumor was considered optimal, but new 
studies have since contradicted this assumption, with 
edges under 1 cm being equally safe. Positive margins 
were found in about 7% of cases according to other 
studies. Analysis of these patients has shown little 
influence on the survival rate (13). 
The British Association of Urological Surgeons 
performed their own set of analyses: their study included 
86 UK centers where 1044 partial nephrectomies were 
practiced within one year. Testing of the resection 
margins was done in 68% of cases, of which only 7% 
were positive, and most positive margins were found in 
stages T3 - 48%, compared to 6% in T1a. According to 
international guidelines for tumor formations below 4 
cm, the primary indication is partial nephrectomy with 
results as good as radical nephrectomy even with the 
presence of positive margin in 6% of the cases (14). 
Positive margins were mainly based on tumor size; the 
surgical technique chosen did not affect their 
appearance. In conclusion, these procedures involved 
higher costs (more frequent imaging invasions), as the 
oncologists worried about long-term relapse or 
metastasis. 
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Another studied attempted to follow the evolution 
of a larger tumor T3 stage. This study followed the 
partial nephrectomy characteristics in renal tumors in 
the T3bNxMx stage with limited tumor renal vein 
thrombosis. Specifically, 305 patients were studied 
between 2004 and 2009, and of these, 2-7% had tumoral 
thrombus in the renal vein and became the subject of 
their study. All patients had one morpho-functional 
kidney, the main reason for partial nephrectomy. On 
none of the 7 patients were positive resection margins 
found. Only one patient required surgical reintervention 
with radical nephrectomy, and he was forced to remain 
on dialysis for the remainder of his life. No local 
metastasis or local recurrence was detected in any 
patient within 30 months after surgery. The approach 
used was mainly pararectal. Studies have showed a 5-
year survival rate of between 47% and 69% (15). 
Trifecta is defined as negative surgical margins, 
zero perioperative complications, and warm ischaemia 
time < 25 minutes. Zargar et al. enhanced this criterion, 
adding 90% glomerular rate preservation and no chronic 
disease stage upgrading. Other authors coined the term 
MIC (negative Margin, Ischaemia no<20 minutes and 
no major complications) (16, 17). 
Kim et al. found a rate of positive surgical margins 
in T1a of 5% versus 6,6% in T1b. The rate of 
achievement of Trifecta for T1a and T1b renal mass was 
65.3% and 43.3%, respectively (P = 0.017), and the rate 
of achievement of Pentafecta was 38.3% and 26.7%, 
respectively (P = 0.172). There is large variation in 
terms of the rate of achievement for Trifecta, ranging 
from 32% to 81%. The overall PSM was 5,8 %, which 
is comparable to other studies (18). 
Logically the use of partial nephrectomy for higher 
risk patients shows superior rates of positive surgical 
margins. Maurice et al., in a large retrospective study, 
reviewed the outcomes of partial nephrectomy in 
patients with more than one adverse pathological 
feature, defined as follows: advanced disease pT3, 
unfavorable histology (sarcomatoid, collecting duct, or 
medullary subtype), high nuclear grade, or any of the 
above three criteria. These researchers found a 8,4% 
positive surgical margins rate, which increased over 
time (19). 
However only surgical volume and the robotic 
approach seem to be independent predictors for positive 
surgical margins after partial nephrectomy (20). Positive 
surgical margin is an independent factor of local 
recurrence but does not impact survival (21). 
Simon et al. performed laparoscopic partial 
nephrectomy with selective control of the renal 
parenchyma by using a special clamp. Their study 
tracked patients who had undergone nephrectomy using 
a new type of vascular clamping that allows selective 
control of renal parenchyma. The study included 
patients with kidney tumors under 4 cm in the T1a and 
T1b stages, and Furhman grade 2 or 3. A Nussbaum 
special clamp was used, which allowed better control of 
renal parenchyma. Three patients aged 60, 64, and 77 
years were considered: none had positive margins. In 
these, the tumor formation was located peripherally, 
which allowed the use of such a clamp. The major 
advantage of using this clamp is that ischemia occurs 
only at the level of the tumor (22). 
Some authors report no or very few PSMs. In a 
retrospective comparison study on 102 patients with 
open and robotic partial nephrectomy, Omer et al. found 
only one case of positive surgical margin (23). This 
finding is consistent with the report of Tufek et al. who 
on 50 patients with robotic assisted partial nephrectomy 
found no positive surgical margins. They used in every 
case an intraoperatory ultrasonography with excellent 
results. Novel techniques with promising results are also 
emerging, such as near-infrared fluorescence after 
intravenous injection of indocyanine green (24, 25). 
Ricciardulli et al., on 316 patients with laparoscopic and 
robotic partial nephrectomy, found positive surgical 
margins in 5% and 0% respectively (26). 
Volpe et al. studied perioperative and renal 
functional outcomes of elective robot-assisted partial 
nephrectomy (RAPN) for renal tumors with high 
surgical complexity. The purpose of their study was 
preoperative and postoperative follow-up on 44 patients 
who underwent robotic assisted partial laparoscopic 
nephrectomy. Twenty-three patients were in the T1b 
stage, the rest in T1a stage. Of these, only 2 were 
diagnosed with positive resection margins (4%), below 
the median described in the literature. Patients were 
followed radiologically for 23 months without local 
recurrence or remote metastases. Prior to surgery, all 
patients benefited from CT, X-ray, and ultrasonography, 
which placed the diagnosis of renal tumor to less than 4 
cm, partial laparoscopic nephrectomy being currently 
the gold standard for the treatment of this type of tumor. 
Uric acid and hemoleucogram levels were monitored 
both before and after surgery. The histopathological 
examination set the diagnosis of benign tumors in 10 
cases. The effectiveness of this type of surgery 
compared to classical partial nephrectomy has been 
demonstrated, with simple laparoscopic, shortened 
operation time, lower blood loss, and faster recovery of 
the patient (27). 
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Jong et al. compared the surgical margin in open vs 
robotic partial nephrectomy. The results were 
interesting, given that positive surgical margins were 
found in 1,8% of open partial nephrectomies versus 
1,3% in robotic partial nephrectomies, that is, surgical 
margins were significantly narrower for the robotic 
surgery. Of the 2 patients who presented local 
recurrence, both had negative surgical margins (28). 
For years, a 1cm margin was considered 
oncologically safe. But recent studies have 
demonstrated that 5 mm margin may also be safe (29). 
The authors proposed a 3 mm margin but sufficient data 
are not available to support this conclusion (30). On the 
other hand, Liu et al., in a study on 118 T1 patients in 
three groups—open radical nephrectomy, open partial 
nephrectomy and laparoscopic partial nephrectomy 
(31)—found that positive surgical margins were 
significantly lower in the open partial nephrectomy than 
in laparoscopic partial nephrectomy. 
 
Conclusions 
Generally, the positive surgical margin may lead to 
local recurrence of neoplasia. Although the recurrence is 
rare (2,2%), nephron-sparing surgery is nevertheless 
quite difficult (32), and is complicated by the fact that it 
involves a reintervention. Even more puzzling is the 
variate time of appearance of the neoplasia, ranging 
from 3 months to 45 years (33, 34). There is currently 
no standard strategy or guideline for this type of disease. 
Few studies have investigated the treatment strategy 
for this neoplasic pathology. Based on 47 patients, 
Johnson et al. reported an overall major perioperative 
complication rate of 19.6%, higher than the rates 
reported in PN series of surgically naive patients. 
However, this rate is understandable, given that each 
anatomical plane is changed and substantial tissue 
scarring occurs (35). Renal clear cell carcinoma is radio 
resistant and thus the use of radiotherapy is of little or 
no use. 
Although surgery remains the gold standard, data 
suggest that (neo)adjuvant chemotherapy can be 
beneficial. Unfortunately, even with this combination, 
the rate of progression is catastrophic as highlighted by 
Margulis et al. (36, 37). The goal of this paper in 
describing several treatment options was to underline 
the importance of identification of PSM, despite the lack 
of a specific correlation between PSM and local relapse. 
Moreover later complications which involve solitary 
kidney pathology and even dyalisis can be avoided (38-
43).  
Intraoperatory ultrasound is the only method which 
is used sufficiently to ascertain an impact on outcomes. 
Although cytology shows promising results, it is 
typically limited by staff experience. The use of 
indocyanine green is promising though still not 
widespred.  
Even more intriguing is the differential diagnosis of 
this pathology with retroperitoneal space pathology (44, 
45). Positive surgical margin needs to be investigated 
more not as a definition, but for means of identification/ 
avoidance that is important for an adequate therapeutic 
approach. 
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